c-Met/HGFR
Os inibidores de c-Met/HGFR visam o Receptor do Fator de Crescimento de Hepatócitos (c-Met), uma tirosina quinase envolvida em processos celulares como crescimento, motilidade e morfogênese. A sinalização de c-Met está implicada na progressão do câncer, na metástase e na resistência às terapias. Inibir o c-Met pode interromper o crescimento e a disseminação do tumor, tornando esses inibidores valiosos na pesquisa sobre o câncer. Na CymitQuimica, oferecemos inibidores de c-Met/HGFR para apoiar sua pesquisa em oncologia, metástase e terapias contra o câncer.
Foram encontrados 128 produtos de "c-Met/HGFR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
JNJ-38877618
CAS:<p>JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).</p>Fórmula:C20H12F2N6Pureza:98.84% - 99.74%Cor e Forma:SolidPeso molecular:374.35Emibetuzumab
CAS:<p>Emibetuzumab: potent humanized MET antibody, antitumor, inhibits HGF/MET pathways, for advanced prostate cancer research.</p>Pureza:SDS-PAGE:96.2%;SEC-HPLC:98.8%Cor e Forma:LiquidPeso molecular:143.74 kDac-Met inhibitor 1
CAS:<p>c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.</p>Fórmula:C17H14N8SPureza:98.77%Cor e Forma:SolidPeso molecular:362.41Bozitinib
CAS:<p>Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability.</p>Fórmula:C20H15F3N8Pureza:99.16%Cor e Forma:SolidPeso molecular:424.38CSF1R-IN-2
CAS:<p>CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).</p>Fórmula:C20H20FN7O2Pureza:99.29%Cor e Forma:SolidPeso molecular:409.42Pamufetinib
CAS:<p>Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase.</p>Fórmula:C27H23FN4O4SPureza:99.39%Cor e Forma:SolidPeso molecular:518.56Onartuzumab
CAS:<p>Onartuzumab (MetMAb) is a humanized monoclonal antibody targeting c-MET, with antitumor effects by blocking HGF and signal transduction.</p>Pureza:97.3%Cor e Forma:LiquidPeso molecular:146.99 kDaRilotumumab
CAS:<p>Rilotumumab (AMG 102) is an HGF-targeting antibody, inhibits HGF/MET signaling, and is used for CRPC and gastric cancer research.</p>Pureza:SDS-PAGE:95% SEC-HPLC:97.51%Cor e Forma:LiquidPeso molecular:145.2 kDaTelisotuzumab
CAS:<p>Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.</p>Pureza:SDS-PAGE:96.4%;SEC-HPLC:98.5%Cor e Forma:LiquidPeso molecular:145.50 kDaSU 5616
CAS:<p>SU 5616 (WAY-608241) regulates abnormal cell proliferation and modulates tyrosine kinase signaling.</p>Fórmula:C13H8ClNOSPureza:98.84%Cor e Forma:SoildPeso molecular:261.73PROTAC c-Met degrader-1
CAS:<p>PROTACc-Met degrader-1 (Compound Met-DD4) is an orally effective PROTAC degrader targeting c-Met with a DC50 of 6.21 nM. It inhibits the proliferation of c-Met-addicted MKN-45 cells with an IC50 of 4.37 nM and causes cell cycle arrest in the G0/G1 phase. In a xenograft mouse model using MKN-45 cells, PROTACc-Met degrader-1 demonstrates antitumor activity.</p>Fórmula:C45H41FN10O5Cor e Forma:SolidPeso molecular:820.87PROTAC c-Met degrader-3
<p>PROTACc-Met degrader-3 (Compound 22b) is a c-Met PROTAC degrader. It facilitates the ubiquitination and degradation of c-Met, with a DC50 of 0.59 nM in EBC-1 cells. PROTACc-Met degrader-3 is applicable in lung cancer research.</p>Fórmula:C51H54N10O7Cor e Forma:SolidPeso molecular:919.037PF-04217903 phenolsulfonate
CAS:<p>PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).</p>Fórmula:C25H22N8O5SPureza:98%Cor e Forma:SolidPeso molecular:546.56Narnatumab
CAS:<p>Narnatumab (IMC-RON8) is a humanized antibody targeting the macrophage-stimulating receptor (RON) with antitumor activity, used in advanced malignant solid tumors research.</p>Pureza:>95%Cor e Forma:LiquidNorleual
CAS:<p>Angiotensin IV analog, potent HGF/c-MET inhibitor (IC50=3 pM), halts MDCK cell growth and invasion, AT4 antagonist, impairs LTP, antiangiogenic.</p>Fórmula:C41H58N8O7Pureza:98%Cor e Forma:SolidPeso molecular:774.951D228
<p>1D228, a c-Met/TRK inhibitor with antitumor properties, suppresses cyclin D1 to precipitate G0/G1 arrest, thereby inhibiting proliferation and migration of</p>Pureza:98%Cor e Forma:Odour SolidFosgonimeton acetate
<p>Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).</p>Fórmula:C29H49N4O10PPureza:98.01%Cor e Forma:SolidPeso molecular:644.69c-Met-IN-18
<p>C-Met-IN-18, an ATP-competitive type-III inhibitor, targets both wild-type (WT) and D1228V mutant c-MET with IC50 values of 0.013 µM and 0.20 µM, respectively.</p>Fórmula:C21H15FN4O2Pureza:98%Cor e Forma:SolidPeso molecular:374.37c-Met-IN-17
<p>c-Met-IN-17 is a potent inhibitor of c-Met kinase, demonstrating an IC50 of 0.031 μM, and is applicable in anticancer research. [1]</p>Fórmula:C21H15FN4O2Pureza:98%Cor e Forma:SolidPeso molecular:374.37c-Met-IN-23
<p>c-Met-IN-23 (Compound 12g) functions as a c-Met inhibitor with an IC50 of 0.052 μM against c-Met. It also inhibits the MDR1 and MRP1/2 pumps in cancerous HepG2 and BxPC3 cells. As such, c-Met-IN-23 serves as an anticancer agent.</p>Fórmula:C16H13N7OPeso molecular:319.11816c-Met-IN-19
<p>c-Met-IN-19 (Compound 21j) is a potent c-Met inhibitor with an IC50 of 1.99 nM and demonstrates cytotoxic effects on various cancer cell lines, including A549,</p>Fórmula:C34H37Cl2FN4O7SPureza:98%Cor e Forma:SolidPeso molecular:735.65Umikibart
<p>Umikibart is a humanized IgG4κ antibody targeting HGF, with the corresponding isotype control being HumanIgG4(S228P) kappa, Isotype Control.</p>Cor e Forma:Odour LiquidC-Met inhibitor D9
CAS:<p>C-Met inhibitor D9 is a c-Met kinase inhibitor.</p>Fórmula:C17H15N3O2Pureza:97%Cor e Forma:SolidPeso molecular:293.32LMTK3-IN-1
CAS:<p>Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway.</p>Fórmula:C18H11F3N4OPureza:99.89%Cor e Forma:SoildPeso molecular:356.3Antitumor agent-111
<p>Antitumor Agent-111 (Compound 46), a c-Met kinase inhibitor (IC50 = 46 nM), exhibits both antitumor and antiproliferative effects.</p>Fórmula:C34H29ClF2N6O5Pureza:98%Cor e Forma:SolidPeso molecular:675.08BMS-777607
CAS:<p>BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3.</p>Fórmula:C25H19ClF2N4O4Pureza:98.16% - 98.56%Cor e Forma:SolidPeso molecular:512.89SYN1143
CAS:<p>SYN1143 (AMG-1) strongly inhibits RON & c-Met with IC50s: 9 & 4 nmol/L.</p>Fórmula:C31H29FN4O5Pureza:99.69%Cor e Forma:SolidPeso molecular:556.58PF-04217903 methanesulfonate
CAS:<p>PF-04217903 methanesulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).</p>Fórmula:C20H20N8O4SPureza:98%Cor e Forma:SolidPeso molecular:468.49BMS-794833
CAS:<p>BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.</p>Fórmula:C23H15ClF2N4O3Pureza:98% - 99.69%Cor e Forma:SolidPeso molecular:468.84NVP-BVU972
CAS:<p>NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.</p>Fórmula:C20H16N6Pureza:97.24% - >99.99%Cor e Forma:SolidPeso molecular:340.38Ningetinib
CAS:<p>Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.</p>Fórmula:C31H29FN4O5Pureza:99.95% - 99.98%Cor e Forma:SolidPeso molecular:556.58Altiratinib
CAS:<p>Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,</p>Fórmula:C26H21F3N4O4Pureza:99.67% - 99.75%Cor e Forma:SolidPeso molecular:510.46BMS817378
CAS:<p>BMS817378 is a potent and selective inhibitor of MET(IC50 : 1.7 nM).</p>Fórmula:C24H18ClF2N4O7PPureza:>99.99%Cor e Forma:SolidPeso molecular:578.85XL092
CAS:<p>XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.</p>Fórmula:C29H25FN4O5Pureza:98.60%Cor e Forma:SolidPeso molecular:528.53Foretinib
CAS:<p>Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.</p>Fórmula:C34H34F2N4O6Pureza:98.07% - 99.68%Cor e Forma:SolidPeso molecular:632.65X-376
CAS:<p>X-376 (Ensartinib) is an orally available small molecule inhibitor of the receptor tyrosine kinase ALK with potential antineoplastic activity.</p>Fórmula:C25H25Cl2FN6O3Pureza:97.87%Cor e Forma:SolidPeso molecular:547.41Afatinib Dimaleate
CAS:<p>Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the EGFR family, with antineoplastic activity.</p>Fórmula:C32H33ClFN5O11Pureza:98.11% - 99.87%Cor e Forma:SolidPeso molecular:718.08Merestinib dihydrochloride
CAS:<p>Merestinib dihydrochloride (LY2801653 dihydrochloride) is a kinase inhibitor with antitumor activity that inhibits MET and MKNK1/2.</p>Fórmula:C30H24Cl2F2N6O3Cor e Forma:SolidPeso molecular:625.45Capmatinib 2HCl.H2O
CAS:<p>Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.</p>Fórmula:C23H21Cl2FN6O2Pureza:99.77%Cor e Forma:SolidPeso molecular:503.36NPS-1034
CAS:<p>NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.</p>Fórmula:C31H23F2N5O3Pureza:98.48%Cor e Forma:SolidPeso molecular:551.54DS-1205
CAS:<p>DS-1205: AXL kinase inhibitor (IC50=1.3 nM), also targets MER, MET, TRKA (IC50s: 63, 104, 407 nM), hinders cell migration and tumor growth.</p>Fórmula:C41H42FN5O7Pureza:99.75%Cor e Forma:SolidPeso molecular:735.8Hepln-13
CAS:<p>Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.</p>Fórmula:C17H13BrN2Pureza:97.67%Cor e Forma:SolidPeso molecular:325.2Capmatinib 2HCl
CAS:<p>Capmatinib 2HCl (INC-280 2HCl), a c-MET inhibitor, is potent (IC50 = 0.13 nM), highly specific, and induces apoptosis in tumor cells.</p>Fórmula:C23H19Cl2FN6OPureza:98.80%Cor e Forma:SolidPeso molecular:485.34AMG-337
CAS:<p>AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337 inhibits MET kinase activity (IC50: < 5 nM).</p>Fórmula:C23H22FN7O3Pureza:99.26% - 99.9%Cor e Forma:SolidPeso molecular:463.46AMG-208
CAS:<p>AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.</p>Fórmula:C22H17N5O2Pureza:98.56%Cor e Forma:SolidPeso molecular:383.4S49076
CAS:<p>S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.</p>Fórmula:C22H22N4O4SPureza:95.35% - 97.4%Cor e Forma:SolidPeso molecular:438.5Golvatinib
CAS:<p>Golvatinib (E-7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor</p>Fórmula:C33H37F2N7O4Pureza:98.24% - ≥95%Cor e Forma:SolidPeso molecular:633.69c-Kit-IN-1
CAS:<p>c-Kit-IN-1 (DCC-2618) is an effective inhibitor of c-Met and c-Kit (IC50s<200 nM).</p>Fórmula:C26H21F2N5O3Pureza:98.72% - 98.73%Cor e Forma:SolidPeso molecular:489.47PHA-665752
CAS:<p>PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.</p>Fórmula:C32H34Cl2N4O4SPureza:97.05% - 98.82%Cor e Forma:SolidPeso molecular:641.61Glumetinib
CAS:<p>Glumetinib (SCC244) (SCC 244) is a novel potent and selective inhibitor of c-Met kinase (IC50: 0.42 nM).</p>Fórmula:C21H17N9O2SPureza:99.79%Cor e Forma:SolidPeso molecular:459.48
